Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05905328
Other study ID # CTA-2101
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date December 28, 2023
Est. completion date June 2027

Study information

Verified date April 2024
Source CytoAgents, Inc.
Contact Arthur Bertolino, MD, PhD, MBA
Phone 6169281145
Email abertolino@cytoagents.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an interventional study to evaluate the use of CTO1681 in preventing or reducing CAR T-cell-induced toxicities like cytokine release syndrome (CRS). This study will enroll adult patients with DLBCL who are scheduled to receive CD19-directed CAR T-cell therapy. The first phase of the study will be open label with dose escalation. Participants will start taking CTO1681 just prior to receiving their CAR T-cell therapy and continue to take the study drug three times daily for a total of 15 days.


Description:

The first phase of the study will be an open-label, dose escalation, safety assessment in a group of patients, and will also collect data to investigate the potential benefit of CTO1681, initiated prior to CAR T-cell therapy, in preventing or reducing certain toxicities or side effects associated with CAR T-cell therapy, such as cytokine release syndrome (CRS). Participants will start taking CTO1681 just prior to receiving their CAR T-cell therapy and continue to take the study drug three times daily for a total of 15 days. Participants will provide blood samples at specified points throughout the study. In addition, urine samples, ECGs, scans, and other medical evaluations will be performed that are associated with the CAR T-cell therapy and/or necessary to verify study eligibility. Participants will be monitored for safety and efficacy for 43 days, and then will have follow-up to continue to monitor for safety and monitor for tumor response for up to 6 months for phase 1.


Recruitment information / eligibility

Status Recruiting
Enrollment 54
Est. completion date June 2027
Est. primary completion date June 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age 18 years or older. 2. Undergone leukapheresis and is scheduled to receive protocol-specified commercially available axicabtagene ciloleucel CD19-directed CAR T-cell therapy for DLBCL without corticosteroid prophylaxis for CRS and/or ICANS. Patients eligible for study must have relapsed or refractory DLBCL after at least one prior line of systemic therapy. 3. Met all inclusion criteria for CAR T-cell therapy per institutional guidelines. 4. Adequate organ function defined as: 1. Estimated Creatinine Clearance per Cockroft Gault formula = 60 mL/min. 2. Serum alanine aminotransferase/aspartate aminotransferase = 2.5 × ULN. 3. Total bilirubin = 1.5 × ULN. 4. Left ventricular ejection fraction = 40% on echocardiogram or multigated acquisition and no clinically significant pericardial effusion. 5. Platelets = 50,000/mm3. 6. Absolute neutrophil count > 1000/µL. 7. Absolute lymphocyte count > 100/µL. 5. Documented measurable lymphoma disease adequate to judge by Lugano Criteria. 6. Eastern Cooperative Oncology Group performance status 0 to 1. 7. Female participants of childbearing potential and all male participants must agree to use Investigator-approved methods of birth control while on study drug and for 30 days thereafter. 8. Patients who are willing to provide written informed consent before the predose procedures, or patients who have a legal representative capable of providing informed consent on their behalf. Exclusion Criteria: 1. Any cytotoxic chemotherapy within 14 days prior to leukapheresis. 2. Clinically significant malabsorption syndromes and swallowing difficulties which are inadequately controlled with medication (eg, odynophagia, dysphagia, gastroesophageal reflux disease) as per Investigator assessment. 3. Grade 2 or greater electrolyte imbalance, per CTCAE v5.0: 1. Potassium < 3.0 or > 5.5 mmol/L 2. Sodium < 130 or > 150 mmol/L 3. Calcium < 8.0 or > 11.5 mg/dL 4. Magnesium < 0.5 or > 1.23 mmol/L 4. Clinically significant ECG abnormality at Screening or Baseline (Day -1), including but not limited to, a confirmed QTcF value > 470 msec. Patients with QTcF readings that are borderline or difficult to interpret because of a condition such as bundle branch block, or in those where the end of the T wave is difficult to measure will be excluded. This also includes any Grade 2 or greater conduction block disorder, atrial, or ventricular arrythmia. 5. History of clinically significant arrhythmia and/or requiring anticoagulation/antiplatelet treatment at therapeutic dose. 6. Any clinically significant (ie, active) cardiovascular disease, including cerebral vascular accident/stroke (< 6 months before enrollment), myocardial infarction (< 6 months before enrollment) or unstable angina, and congestive heart failure = New York Heart Association Classification Class III. 7. Uncontrolled thromboembolic events or recent severe hemorrhage within the last 6 months. 8. Known history of any bleeding disorder. 9. Requirement for ongoing therapeutic doses of anticoagulant therapy, antiplatelet or fibrinolytic agents (low molecular weight heparin prophylaxis is allowed). 10. Baseline systolic blood pressure <100 mmHg. 11. History of autoimmune disease/ graft versus host disease requiring immunosuppressive therapy within the last 2 years. However, physiologic steroids (prednisone equivalent) may be given at a dose of 5 mg or less. 12. Patients who, in the opinion of the Investigator, would be unlikely to comply with study procedures or are otherwise unsuitable for enrollment.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
CTO1681 10 µg
Administered 3 times daily for 15 days (initial cohort).
CTO1681 20 µg
Administered 3 times daily for 15 days (successive cohort).
CTO1681 30 µg
Administered 3 times daily for 15 days (successive cohort).

Locations

Country Name City State
United States Alison Sehgal Pittsburgh Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
CytoAgents, Inc. TFS HealthScience

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of adverse events (AEs) AEs graded by CTCAE v5.0 6 months following start of treatment
Secondary Incidence of CRS (any grade) CRS graded by ASTCT Consensus Grading 6 months following the start of treatment
Secondary Incidence of ICANS (any grade) ICANS graded by ASTCT Consensus Grading 6 months following the start of treatment
Secondary Incidence of hospitalizations Unplanned hospitalizations 6 months following the start of treatment
Secondary Use of other anticytokine therapies Use of cytokine mitigating therapies other than CTO1681 6 months following the start of treatment
Secondary Proinflammatory cytokine levels Concentration of proinflammatory cytokines in the blood 6 months following the start of treatment
Secondary Concentration of CTO1681 Concentration of CTO1681 in the blood Baseline, Day 0, Day 2, Day 4, Day 6, Day 13
Secondary CAR T-cell concentration in blood Concentration of CAR T-cell measured using ddPCR 6 months following the start of treatment
Secondary CAR T-cell antitumor response Antitumor response assessment using the Lugano Criteria 6 months following the start of treatment
See also
  Status Clinical Trial Phase
Completed NCT03685383 - Cytokine Adsorption in Post-cardiac Arrest Syndrome in Patients Requiring Extracorporeal Cardiopulmonary Resuscitation N/A
Terminated NCT04540120 - Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome Phase 2
Terminated NCT03557749 - Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies
Active, not recruiting NCT04150913 - A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity Phase 2
Completed NCT04643678 - Anakinra in the Management of COVID-19 Infection Phase 2/Phase 3
Recruiting NCT04975555 - Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy Phase 2
Terminated NCT04403685 - Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers Phase 3
Completed NCT04366908 - Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome Phase 2
Completed NCT05349669 - Jafron Haemoadsorption During Cardiopulmonary Bypass Phase 2
Completed NCT04720378 - Safety and Tolerability Study of IV ST266 in COVID-19 Subjects Phase 1
Terminated NCT04415073 - A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19 Phase 2
Completed NCT03533101 - Tocilizumab for Cytokine Release Syndrome Prophylaxis in Haploidentical Transplantation Phase 1/Phase 2
Completed NCT04403061 - Th1/Th2/Th17/TREG and TLRs Activation/KIR for COVID 19 Prediction of Outcome
Recruiting NCT05414162 - Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy
Terminated NCT04377503 - Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19 Phase 2
Completed NCT04475588 - Efficacy and Safety of Itolizumab in COVID-19 Complications Phase 2
Recruiting NCT04781803 - Cyclosporine on Day Zero as Prophylaxis for Cytokine Release Syndrome Phase 2
Completed NCT01353157 - Study of the Clinical Scoring System and Cytokines for Prediction of Inflammatory Response in Major Surgery N/A
Completed NCT04048525 - Cytokine Removal With CVVHD Compared to CVVH N/A
Recruiting NCT04048434 - Extracorporeal Cytokine Adsorption as Additive Treatment of CAR-T Associated Cytokine Release Syndrome (CRS) N/A